Emergent BioSolutions | EBS - Aktuelle Verpflichtungen





Aktuelle Verpflichtungen Veränderung Datum
Acadia Pharmaceuticals USD 305.52M 28.41M 2026-03
Akebia Therapeutics USD 173.88M 10.95M 2026-03
ALKERMES USD 599.5M 56.06M 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Amarin USD 179.64M 14.82M 2026-03
ANI Pharmaceuticals USD 239.51M 38.6M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Coherus Biosciences USD 140.39M 231.91M 2025-12
Emergent BioSolutions USD 651.3M 12.7M 2023-12
Exelixis USD 370.98M 34.67M 2026-03
Glaxosmithkline GBP 28.82B 144.79M 2025-12
Heron Therapeutics USD 90.52M 5.58M 2026-03
Ionis Pharmaceuticals USD 717M 66M 2026-03
Ironwood Pharmaceuticals USD 236.31M 5.91M 2026-03
Lexicon Pharmaceuticals USD 9.9M 10.97M 2026-03
Lonza CHF 3.57B 421M 2025-12
Merck USD 26.94B 1.38B 2026-03
Moderna USD 2.4B 408M 2026-03
Myriad Genetics USD 130.2M 3.6M 2026-03
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Pacira USD 108.79M 11.8M 2026-03
Pfizer USD 34.35B 2.64B 2026-03
PTC Therapeutics USD 923.6M 44.82M 2026-03
Sanofi EUR 30.01B 1.66B 2026-03
Sarepta Therapeutics USD 499.16M 596.13M 2026-03
United Therapeutics USD 599.1M 38.5M 2026-03
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12
Xoma USD 28.3M 6.81M 2025-09